Adjuvant gestagen therapy of endometrial carcinoma (author's transl)

Reference is made in this paper to histological findings, with the view to presenting the results of preoperative gestagen therapy, using hydroxyprogesterone capronate, applied to 334 patients with endometrial carcinomas. Complete tumour regression was achieved in 8.7 per cent of these cases. Furthe...

Full description

Saved in:
Bibliographic Details
Published inZentralblatt für Gynäkologie Vol. 103; no. 21; p. 1289
Main Author Bochmann, J W
Format Journal Article
LanguageGerman
Published Germany 1981
Subjects
Adenocarcinoma - drug therapy
Adult
Female
Humans
Hydroxyprogesterones - therapeutic use
Hysterectomy
Middle Aged
Neoplasm Staging
Progesterone Congeners - therapeutic use
Prognosis
Uterine Neoplasms - drug therapy
Uterine Neoplasms - pathology
Online AccessGet more information

Cover

More Information
Summary:Reference is made in this paper to histological findings, with the view to presenting the results of preoperative gestagen therapy, using hydroxyprogesterone capronate, applied to 334 patients with endometrial carcinomas. Complete tumour regression was achieved in 8.7 per cent of these cases. Further differentiation and increased secretion of the tumour cell were recorded in 56.6 per cent. No gestagen effect at all was recordable from 34.7 per cent only.--Sensitivity of endometrial carcinomas to gestagens was at its highest in cases of highly differentiated adenocarcinomas, in premenopausal women, in the presence of oestrogenic colpocytological reaction, and when endometrial carcinomas coincided with adipositas and diabetes mellitus.--Five-year survival rates, following surgery in combination with hormonal therapy, reached 91,3 per cent and thus were in excess of the 78.6 per cent recorded from patients with surgical treatment alone.
ISSN:0044-4197